Please login to the form below

Not currently logged in
Email:
Password:

Medical device M&A hit 'all-time high' in 2014

Deals last year were led by Medtronic’s acquisition of Covidien

Medtronic headquarters 

Mergers and acquisitions in the medical devices industry hit an all-time high last year, led by Medtronic's acquisition of Covidien - a deal that created the sector's largest company.

Analysis by GlobalData put 2014's M&A activity up 18.5% compared to 2013, with 96 mergers and acquisitions announced during the last 12 months.

Niharika Midha, GlobalData's medical devices analyst, said: “A considerable number of deals in 2014 involved larger companies swallowing up smaller ones with novel technologies that were clinically proven to be superior to existing devices.

“This sets the tone for the coming years, as the medical device industry consolidates into fewer prominent players that directly compete with each other and innovation is fuelled by heightened demand.”

The largest deal of the year was Medtronic's $42.9bn acquisition of Covidien, which faced some criticism that it was motivated by tax inversion, though some analysts have suggested the move was a tactical one, given Covidien's established status in the sector.

Covidien has been expanding its business in patient monitoring and hospital services, including generating promising revenue.

Midha noted that companies with an extensive product portfolio tend to have a competitive advantage in the current industry trends.

She added: “The demand side is displaying an increasing preference for manufacturers that offer a one-stop solution for all their needs.”

The spike in medical devices activity in 2014 mirrors that seen in the pharma sector, where last year's deals included Merck's $9.5bn acquisition of Cubist in addition to paying $3.85bn for Idenix Pharmaceuticals.

Article by
Kirstie Pickering

15th January 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics